Overview

Preventing Osteoporosis Using Denosumab

Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.
Phase:
Phase 4
Details
Lead Sponsor:
Susan L. Greenspan
University of Pittsburgh
Collaborators:
National Institute on Aging (NIA)
National Institutes of Health (NIH)
Treatments:
Calcium
Calcium, Dietary
Denosumab
Ergocalciferols
Vitamin D
Vitamins
Zoledronic Acid